

Table 1. Baseline characteristics of each group of AD patients

	Group D			Group G			Group R		
	D → G	D → R	<i>P-value</i>	G → D	G → R	<i>P-value</i>	R → D	R → G	<i>P-value</i>
Number of patients	90	11		17	32		9	12	
Gender (male, %)	63.5	84.2		65.2	71.7		93.8	81.8	
Age (y)	79.0 ± 8.0	80.6 ± 7.5	0.620	78.6 ± 7.6	79.7 ± 8.6	0.421	82.4 ± 4.7	83.0 ± 6.2	0.842
Education (y)	11.1 ± 1.8	9.0 ± 0.0	0.234	10.5 ± 2.3	10.3 ± 1.4	0.971	12.0 ± 3.0	10.8 ± 1.8	0.514
Clinical scores									
MMSE	19.1 ± 5.4	19.9 ± 6.3	0.600	16.9 ± 5.4	19.1 ± 4.0	0.122	20.3 ± 7.9	20.4 ± 4.4	0.336
HDS-R	16.3 ± 6.2	16.7 ± 6.8	0.926	13.6 ± 5.9	17.2 ± 5.9	0.056	18.8 ± 8.0	20.2 ± 5.1	0.939
GDS	6.2 ± 3.9	5.0 ± 4.5	0.354	5.6 ± 4.4	5.4 ± 3.3	0.964	6.5 ± 2.9	5.0 ± 5.2	0.578
AS	19.8 ± 10.7	14.9 ± 10.4	0.098	18.6 ± 11.5	19.4 ± 6.3	0.297	16.4 ± 8.8	17.3 ± 7.0	0.581
ABS	5.3 ± 5.7	3.6 ± 4.6	0.341	5.3 ± 8.2	4.7 ± 6.3	0.650	2.3 ± 3.0	6.5 ± 8.8	0.271
ADL	16.2 ± 8.2	20.9 ± 4.4	0.276	20.4 ± 6.1	19.5 ± 5.5	0.748	20.2 ± 8.5	17.5 ± 6.1	0.256

Abbreviations: ABS, Abe's BPSD score; AD, Alzheimer's disease; ADL, Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory; AS, apathy scale; D, Donepezil; G, Galantamine; GDS, geriatric depression scale; HDS-R, Hasegawa dementia rating scale; MMSE, mini-mental state examination; R, Revastigmine.

Fig. 1 Drug doses before and after drug switch




Fig. 2 Clinical assessment of patients before and after drug switch

